T-DMI, a combination of trastuzumab (Herceptin) and a cell-killing agent developed by ImmunoGen, has demonstrated superior progression-free survival when compared to just Herceptin and chemotherapy. A Phase II trial with 137 patients with HER2-positive metastatic breast cancer focused on T-DMI as the initial breast cancer treatment...
More...